MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
9.08
-0.15
-1.63%
After Hours: 8.95 -0.13 -1.44% 17:21 03/05 EST
OPEN
9.09
PREV CLOSE
9.23
HIGH
9.33
LOW
8.93
VOLUME
412.44K
TURNOVER
--
52 WEEK HIGH
18.23
52 WEEK LOW
8.12
MARKET CAP
315.50M
P/E (TTM)
134.32
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: CervoMed (CRVO) and Delcath Systems (DCTH)
TipRanks · 18h ago
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma
TipRanks · 2d ago
Delcath Systems CEO Gerard J Michel Acquires Common Shares
Reuters · 2d ago
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), SOPHiA GENETICS (SOPH) and InfuSystem Holdings (INFU)
TipRanks · 2d ago
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
TipRanks · 2d ago
Delcath Systems Publishes CHOPIN Phase 2 Trial Results in The Lancet Oncology
Reuters · 2d ago
DELCATH SYSTEMS ANNOUNCES PUBLICATION OF CHOPIN CLINICAL TRIAL RESULTS IN THE LANCET ONCOLOGY
Reuters · 2d ago
Delcath: Fundamentals Intact, Despite Share Price Weakness
Seeking Alpha · 3d ago
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.